Compass Pathways Plc (NASDAQ: CMPS) — Company Overview, News & Financial Data
Compass Pathways focuses on psilocybin therapy to address treatment-resistant depression, aiming to revolutionize mental health care.
Compass Pathways Plc
Compass Pathways (NASDAQ:CMPS) operates in the field of mental health care, specializing in developing innovative therapies to address a range of mental health conditions. The company is particularly focused on exploring the potential of psilocybin therapy for treatment-resistant depression, a significant and growing challenge in mental health care. Compass Pathways is actively engaged in clinical trials and research projects aimed at understanding and harnessing the therapeutic benefits of psychedelics. Their objective is to revolutionize the approach to mental health treatment, making effective and innovative therapies accessible to those in need. Compass Pathways is dedicated to improving patient outcomes and advancing mental health care through scientific research and development.
Snapshot
Operations
Products and/or services of Compass Pathways Plc
- COMP360 (psilocybin therapy) is a synthetic psilocybin formulation for treatment-resistant depression (TRD).
- Digital therapeutic platforms support the deployment and scaling of COMP360, enriching patient experience and therapy outcomes.
- Strategic partnerships with academic and clinical institutions to advance psychedelic therapy research.
- Personalized therapy programs designed to work alongside COMP360, integrating patient-specific treatment approaches.
- Advanced training programs for therapists focusing on the delivery of psychedelic-assisted therapies, ensuring high-quality clinical support.
- Investment in innovative research on other psychedelic substances to expand their therapeutic portfolio beyond psilocybin.
Compass Pathways Plc executive team
- Kabir Kumar NathCEO & Executive Director
- Teri LoxamChief Financial Officer
- Guy GoodwinChief Medical Officer
- Stephen D. SchultzSenior Vice President of Investor Relations
- Kelley BoucherChief People Officer
- Lars Christian WildeSenior Advisor
- Susan C. StansfieldAdvisor
- Michael GoldChief Research & Development Officer
- Lori EnglebertChief Commercial Officer
- Steve LevineChief Patient Officer
Latest news about Compass Pathways Plc
Compass Pathways reports durable depression trial data
United StatesCompass Pathways swings to Q1 profit on warrant gains and massive cash influx
United StatesCompass Pathways reports 2025 results, cash runway extended into 2028
United StatesCompass Pathways advances COMP360 into late-stage PTSD trials
United States
Key financials
Reported results for Compass Pathways Plc, in USD.
- Market cap
- 1.7B
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.8
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -179M | -287.9M | |
| 0 | -178.2M | -155.1M | |
| 0 | -136.9M | -118.5M | |
| 0 | -110.4M | -91.5M |